NIKKEI 225
38,814.38 +324.21 (+0.84%) HANG SENG
18,530.81 +105.85 (+0.57%) CRUDE OIL
74.46 +0.39 (+0.53%) GOLD FUTURES
2,388.30 +12.80 (+0.54%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,476.52 +116.07 (+0.21%)
GILD Jun 2024 62.500 call
| Previous close | 1.9500 |
| Open | 1.5500 |
| Bid | 1.8600 |
| Ask | 1.9600 |
| Strike | 62.50 |
| Expiry date | 2024-06-21 |
| Day's range | 1.5500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 289 |
Business WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
BenzingaNational Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months. Gilead Sciences Inc. (NASDAQ:GILD) sponsored and funded the studies implemented through the HIV Prevention T
ZacksThe Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.
